BRAF and colorectal carcinoma: For example, MSI-H was found to be a marker of better prognosis among CRC patients in a meta-analysis (OR = 0.58; 95% CI 0.47–0.72), and patients with BRAF mutation were found to have significantly worse progression-free survival compared with BRAF wild-type patients (HR = 1.33; 95% CI 1.12–1.57) [33, 34].